Story detail view · 2026-07
New study supports testing of Merck’s Ebola vaccine in DRC outbreak

New study supports testing of Merck’s Ebola vaccine in DRC outbreak

Quick Summary

New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500